The ALS Investment Fund is a venture capital firm that invests in biotechnology companies developing treatments for neurodegenerative diseases, with a specialized focus on Amyotrophic Lateral Sclerosis (ALS). Their strategy involves rigorous due diligence and investing in seed-stage to Series A companies, aiming to generate financial returns by accelerating transformative healthcare solutions.
67% of their portfolio is in Biotech & Life Sciences. Average disclosed round size is $45.3M (across 3 rounds with reported amounts).
Portfolio
3
Fund Size
—
Top Stage
Series B
Last 12 Mo
0
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
3 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Qualis Corporation | Series B | $88M | Mar 2023 |
 Bloom Science | Series A | $12M | Dec 2021 |
 Emulate Inc. | Series C | $36M | Jun 2018 |
Top Co-Investors
EQT Life Sciences1 shared
Sanofi Ventures1 shared
Mission BioCapital1 shared
INKEF Capital1 shared
Dementia Discovery Fund1 shared
Amgen1 shared
Mitsui Global Investment1 shared
Dolby Family Ventures1 shared
Leaps by Bayer1 shared
Joyance Partners1 shared
Founders Fund1 shared
Scifi VC1 shared
Last updated: 28 April 2026